Physician profile
Ming Yeong Lim
NPI 1184855751
$93,923.66
in general payments reported to CMS, 2019-2025
11 companies · $25K in 2025
The $25K reported for 2025 was more than what 94% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,838 · 2020: $4,835 · 2021: $5,520 · 2022: $4,911 · 2023: $22K · 2024: $29K · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $62K · Travel and Lodging: $6,625 · Honoraria: $4,900 · Food and Beverage: $1,892 · Education: $5.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $62,396.30 |
| Travel and Lodging | $6,624.98 |
| Honoraria | $4,900.00 |
| Food and Beverage | $1,892.26 |
| Education | $5.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $39,956.63 | 2020-2025 | |
| Hema Biologics, LLC | $13,794.52 | 2021-2025 | Sevenfact, Sevenfact |
| Alexion Pharmaceuticals, INC. | $13,143.82 | 2022-2023 | Ultomiris |
| E.R. Squibb & Sons, L.L.C. | $11,678.33 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $5,060.59 | 2022-2023 | |
| Biomarin Pharmaceutical INC. | $3,477.80 | 2024 | Roctavian |
| Novo Nordisk INC | $3,195.99 | 2019-2020 | |
| Dova Pharmaceuticals | $3,000.00 | 2021 | |
| Octapharma USA, INC. | $443.02 | 2019-2023 | Wilate - Von Willebrand Factor/Coagulation Factor Viii Complex (Human) |
| Bayer Healthcare Pharmaceuticals INC. | $172.96 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ming Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.